Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 129 results for "Tecfidera Treated Patients"

Long-Term Study Supports Benefits of Treating MS at First Possible Signs
Neurology Today

Long-Term Study Supports Benefits of Treating MS at First Poss...

An 11-year follow-up study of patients with clinically isolated syndrome indicates that early treatment with interferon beta-1b had a long-lasting, even remote beneficial effect on disease activity as well as cognitive outcomes, resource ... Neurology Today, 2 months ago

1 images for "Tecfidera Treated Patients"

European Pharmaceutical Review, 6 months ago

New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting

− TECFIDERA Treatment Significantly Reduced Time to First Relapse vs. Glatiramer Acetate, Interferon β and Teriflunomide and Showed Comparable Efficacy to Fingolimod in Data Analysis from MSBase Registry − − Benefit-Risk Profile of ... month ago Tecfidera® real-world studies affirm sustained efficacy and safety profile  Hospital Pharmacy Europe1 month ago BIOGEN : New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting  4 Traders1 month ago Biogen Release: New Data Affirm Strong Efficacy And Well-Characterized Safety Profile Of TECFIDERA In Both Clinical Studies And Real-World Setting  BioSpace1 month ago

Biogen Reveales Efficacy, Safety Data For Tecfidera In MS Trials

The new data will be presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis in London. Using data sourced from the global MSBase registry and propensity score matching, researchers compared relapse ...
 Nasdaq1 month ago Biogen says real-world data affirm positive effects of MS drug Tecfidera seen in clinical trials  FirstWord Pharma1 month ago Biogen reports positive data for MS drug Tecfidera in clinical, real-world settings  FirstWord Pharma1 month ago

Biogen aims real-world data at Tecfidera's patient drop-out problem

Biogen's multiple sclerosis drug Tecfidera has a problem: Arelatively high number of patients start the drug, only to stop taking it later. But now, the company hastrotted out some real-world data it thinks can help turn that problem around. The ...
 FiercePharma1 month ago Biogen takes on Tecfidera adherence issues  pharmaphorum1 month ago

Actelion Using Combination Strategy to Attack Multiple Sclerosis

Actelion Ltd. is seeking more effective treatments for people suffering from multiple sclerosis by following a strategy that's worked in treating HIV, cancer and heart failure -- combining medicines to increase their potency. The company has begun ...
 Bloomberg3 days ago Actelion to investigate all-oral MS combination therapy  Reuters India3 weeks ago Actelion nimmt Studie zur Untersuchung einer rein oralen Kombinationstherapie bei Patienten mit schubförmiger Multipler Sklerose auf  Quotenet.com3 weeks ago Actelion : to investigate all-oral combination therapy for patients with relapsing multiple sclerosis  4 Traders3 weeks ago

Orphan designation: Dimethyl fumarate, for the: Treatment of bullous pemphigoid

orphan designation (EU/3/16/1698) was granted by the European Commission to Immungenetics AG, Germany, for dimethyl fumarate for the treatment of bullous pemphigoid. What is bullous pemphigoid? Bullous pemphigoid is an autoimmune skin disease ...
 European Medicines Agency1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 8, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency2 months ago

Roche's Ocrelizumab Expected To Introduce Major Shifts In The Treatment Paradigm For Multiple Sclerosis

By a News Reporter-Staff News Editor at Biotech Week -- There is high anticipation for Roche's ocrelizumab, a monoclonal antibody that was granted "Breakthrough Therapy Designation" by the FDA earlier this year for its potential indication in ...
 4 Traders2 days ago Roche's MS hopeful Ocrevus banks more data for fierce market-share combat  FiercePharma1 month ago

Antidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval

The following Factor Xa inhibitors, which serve as blood-thinner drugs, are being used by an increasing number of patients for stroke prevention and for treatment of deep vein thrombosis and pulmonary embolism: Eliquis (apixaban) from ...
 DrugInjuryLaw.com2 months ago

Actelion's (ALIOF) CEO Jean-Paul Clozel on Q3 2016 Results - Earnings Call Transcript

Actelion Ltd. ( OTCPK:ALIOF ) Q3 2016 Earnings Conference Call October 20, 2016 7:00 AM ET Executives Andrew Weiss - Head, IR and Corporate Communications Jean-Paul Clozel - CEO Otto Schwarz - COO André Muller - CFO Guy Braunstein ...
 Seeking Alpha2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less